{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:46:32Z","timestamp":1792701992597,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40265-022-01746-8","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T09:06:53Z","timestamp":1657703213000},"page":"1213-1220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":137,"title":["Tirzepatide: First Approval"],"prefix":"10.1007","volume":"82","author":[{"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,13]]},"reference":[{"key":"1746_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","volume":"18","author":"T Coskun","year":"2018","unstructured":"Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3\u201314.","journal-title":"Mol Metab."},{"key":"1746_CR2","unstructured":"Eli Lilly and Company. Medicines in development: molecule & potential indication data as of April 28, 2022. https:\/\/www.lilly.com\/discovery\/clinical-development-pipeline. Accessed 23 June 2022."},{"key":"1746_CR3","unstructured":"Eli Lilly and Company. Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1 [media release]. https:\/\/www.lilly.com\/. Accessed 28 Apr 2022."},{"issue":"1","key":"1746_CR4","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12933-021-01412-5","volume":"20","author":"EZ Fisman","year":"2021","unstructured":"Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021;20(1):225.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1746_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s13300-020-00981-0","volume":"12","author":"T Min","year":"2021","unstructured":"Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diabetes Ther. 2021;12(1):143\u201357.","journal-title":"Diabetes Ther."},{"key":"1746_CR6","unstructured":"U.S. Food & Drug Administration. FDA approves novel, dual-targeted treatment for type 2 diabetes [media release]. https:\/\/www.fda.gov\/. Accessed 13 May 2022."},{"key":"1746_CR7","unstructured":"Eli Lilly and Company. MOUNJAROTM (tirzepatide) injection, for subcutaneous use: US prescribing information. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215866s000lbl.pdf. Accessed 23 Jun 2022."},{"issue":"2","key":"1746_CR8","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","volume":"106","author":"MK Thomas","year":"2021","unstructured":"Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021;106(2):388\u201396.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1746_CR9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1210\/clinem\/dgab722","volume":"107","author":"V Pirro","year":"2021","unstructured":"Pirro V, Roth KD, Lin Y, et al. Effects of tirzepatide, a dual GIP and GLP-1 RA, on lipid and metabolite profiles in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2021;107(2):363\u201378.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1746_CR10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/dom.14553","volume":"24","author":"JM Wilson","year":"2022","unstructured":"Wilson JM, Lin Y, Luo MJ, et al. The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis. Diabetes Obes Metab. 2022;24(1):148\u201353.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1746_CR11","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1111\/dom.14174","volume":"22","author":"JM Wilson","year":"2020","unstructured":"Wilson JM, Nikooienejad A, Robins DA, et al. The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes Obes Metab. 2020;22(12):2451\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1746_CR12","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.2337\/dc19-1892","volume":"43","author":"ML Hartman","year":"2020","unstructured":"Hartman ML, Sanyal AJ, Loomba R, et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care. 2020;43(6):1352\u20135.","journal-title":"Diabetes Care"},{"issue":"2","key":"1746_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/dom.14572","volume":"24","author":"K Furihata","year":"2022","unstructured":"Furihata K, Mimura H, Urva S, et al. A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes. Diabetes Obes Metab. 2022;24(2):239\u201346.","journal-title":"Diabetes Obes Metab"},{"issue":"10160","key":"1746_CR14","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","volume":"392","author":"JP Frias","year":"2018","unstructured":"Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392(10160):2180\u201393.","journal-title":"Lancet"},{"issue":"6","key":"1746_CR15","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/dom.13979","volume":"22","author":"JP Frias","year":"2020","unstructured":"Frias JP, Nauck MA, Van J, et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab. 2020;22(6):938\u201346.","journal-title":"Diabetes Obes Metab"},{"issue":"10295","key":"1746_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143\u201355.","journal-title":"Lancet"},{"issue":"6","key":"1746_CR17","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Frias","year":"2021","unstructured":"Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315.","journal-title":"N Engl J Med"},{"issue":"10300","key":"1746_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"Ludvik B, Giorgino F, Jodar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583\u201398.","journal-title":"Lancet"},{"issue":"6","key":"1746_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S2213-8587(22)00077-8","volume":"10","author":"T Battelino","year":"2022","unstructured":"Battelino T, Bergenstal RM, Rodr\u00edguez A, et al. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):407\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1746_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(22)00070-5","author":"A Gastaldelli","year":"2022","unstructured":"Gastaldelli A, Cusi K, Fern\u00e1ndez Land\u00f3 L, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022. https:\/\/doi.org\/10.1016\/s2213-8587(22)00070-5.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10313","key":"1746_CR21","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811\u201324.","journal-title":"Lancet"},{"issue":"6","key":"1746_CR22","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","volume":"327","author":"D Dahl","year":"2022","unstructured":"Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534\u201345.","journal-title":"JAMA"},{"key":"1746_CR23","unstructured":"US National Institutes of Health. ClinicalTrials.gov. 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03861052. Accessed 23 June 2022."},{"key":"1746_CR24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"issue":"3","key":"1746_CR25","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","volume":"28","author":"N Sattar","year":"2022","unstructured":"Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591\u20138.","journal-title":"Nat Med"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01746-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01746-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01746-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T06:05:45Z","timestamp":1661321145000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01746-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1746"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01746-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"13 July 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yahiya Y. Syed is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}